Phlebotomy and bolus subcutaneous deferoxamine in Algerian patients with thalassemia major or intermedia or sickle cell disease treated with hydroxyurea

被引：0
|
作者：
Bradai, Mohamed [1 ]
Bachir, Dora [2 ]
De Montalembert, Mariane [3 ]
机构：
[1] Hop Franz Fanon, Serv Hematol, Blida, Algeria
[2] Hop Henri Mondor, Ctr Drepanocytose, F-94010 Creteil, France
[3] Hop Necker Enfants Malad, Serv Pediat Gen, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3812
引用
收藏
页码：20B / 21B
页数：2
相关论文
共 50 条
  • [31] RENAL ABNORMALITIES IN PATIENTS WITH BETA-THALASSEMIA MAJOR (BETA-TM) TREATED WITH CHRONIC SUBCUTANEOUS (SQ) DEFEROXAMINE (DF)
    WAYNE, AS
    ROSENBLUM, ND
    SALLAN, D
    RINK, LM
    DAVIES, KJ
    PEARSON, HA
    BLOOD, 1993, 82 (10) : A476 - A476
  • [32] Treatment with Deferasirox Effectively Decreases Iron Burden in Patients with Sickle Cell Disease and Thalassemia Intermedia.
    Voskaridou, Ersi
    Plata, Eleni
    Stefanitsi, Panagiota
    Douskou, Marousa
    Christoulas, Dimitrios
    Terpos, Evangelos
    BLOOD, 2009, 114 (22) : 608 - 609
  • [33] Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea
    Maluf, Sharbel
    Pra, Daniel
    Friedrisch, Joao R.
    Bittar, Christina
    da Silva, Maria A. Lima
    Henriques, Joao A.
    Silla, Lucia
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2009, 27 (01) : 26 - 29
  • [34] European register of patients with sickle cell disease treated with hydroxyurea is being set up
    Davies, SC
    Roberts-Harwood, M
    BRITISH MEDICAL JOURNAL, 1998, 317 (7157): : 541 - 542
  • [35] Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea
    Kattamis, A
    Lagona, E
    Orfanou, I
    Psichou, F
    Ladis, V
    Kanavakis, E
    Metaxotou-Mavrommati, A
    Kattamis, C
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2004, 21 (04) : 335 - 342
  • [36] Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease
    Barbu, Emilia Alina
    Dominical, Venina M.
    Mendelsohn, Laurel
    Thein, Swee Lay
    PLOS ONE, 2019, 14 (12):
  • [37] Hydroxyurea Is Associated with Early Onset Malaria Episode in Treated Sickle Cell Disease Patients
    Guindo, Aldiouma
    Sarro, Yeya dit Sadio
    Toure, Boubacari Ali
    Fane, Baba
    Coulibaly, Mody
    Diallo, Oumahane Ouane
    Dorie, Alain
    Diallo, Dapa Aly
    BLOOD, 2016, 128 (22)
  • [38] Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
    Delea, Thomas E.
    Hagiwara, May
    Thomas, Simu K.
    Baladi, Jean-Francois
    Phatak, Pradyumna D.
    Coates, Thomas D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (04) : 263 - 270
  • [39] Comparative Study of Radiographic and Laboratory Findings Between Beta Thalassemia Major and Beta Thalassemia Intermedia Patients With and Without Treatment by Hydroxyurea
    Foroughi, Amin Abolhasani
    Ghaffari, Hosein
    Haghpanah, Sezaneh
    Nazeri, Masoume
    Ghaffari, Roghieh
    Bardestani, Marzieh
    Karimi, Mehran
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2015, 17 (02)
  • [40] Effect of Hydroxyurea on Microalbuminuria in Patients with Sickle Cell Disease
    Sah, Jeetendra
    Lalan, Shwetal
    Peichev, Mario
    Viswanathan, Kusum
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S20 - S20
12345